FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,847 | -99.9% | 381,770 | +152.5% | 0.02% | +14.3% |
| Q3 2022 | $3,407,000 | +87.4% | 151,216 | +108.6% | 0.01% | +366.7% |
| Q2 2022 | $1,818,000 | +711.6% | 72,498 | +2720.9% | 0.00% | +200.0% |
| Q2 2021 | $224,000 | -69.8% | 2,570 | -71.4% | 0.00% | -50.0% |
| Q1 2021 | $741,000 | +1584.1% | 9,000 | -30.8% | 0.00% | – |
| Q4 2015 | $44,000 | – | 13,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |